^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    CTRC-NTRK1 fusion

    i
    Other names: CTRC, hymotrypsin C, Caldecrin, Chymotrypsin-C, Elastase 4, CLCR, Serum Calcium Decreasing Factor, Chymotrypsin C (Caldecrin), Elastase IV, ELA4, NTRK1, MTC, TRK, TRKA, Neurotrophic tyrosine kinase, receptor, type 1
    Entrez ID:
    4914; 11330
    Related biomarkers:
    Expression
    Mutation
    Fusion
    Others
    Associations

    News

    Trials
    4years
    Tumour response to TRK inhibition in a patient with pancreatic adenocarcinoma harbouring an NTRK gene fusion. (PubMed, Ann Oncol)
    Targeted TRK inhibition with larotrectinib in PDAC harbouring a CTRC-NTRK1 gene fusion is well tolerated and can improve quality of life for the patient. However, acquired resistance to therapy can emerge in some patients. Next-generation TRK inhibitors such as selitrectinib are currently in development to overcome this resistance (NCT02576431; NCT03215511).
    Clinical • Journal
    |
    BRAF (B-raf proto-oncogene) • NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase) • CTRC (Chymotrypsin C)
    |
    BRAF V600E • BRAF V600 • NTRK1 fusion • CTRC-NTRK1 fusion • NTRK fusion
    |
    Mekinist (trametinib) • Tafinlar (dabrafenib) • Vitrakvi (larotrectinib) • gemcitabine • albumin-bound paclitaxel • oxaliplatin • irinotecan • leucovorin calcium • Hepacid (pegargiminase) • fluorouracil topical • selitrectinib (BAY 2731954)